FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2038068436> ?p ?o ?g. }

• W2038068436 abstract "Acromegaly, an orphan disease usually caused by a benign pituitary tumour, is characterised by hyper-secretion of growth hormone (GH) and insulin-like growth factor I (IGF-1). It is associated with reduced life expectancy, cardiovascular problems, a variety of insidiously progressing detrimental symptoms and metabolic malfunction. Treatments include surgery, radiotherapy and pharmacotherapy. Pegvisomant (PEG) is a genetically engineered GH analogue licensed as a third or fourth line option when other treatments have failed to normalise IGF-1 levels. Evidence about effectiveness and cost-effectiveness of PEG was systematically reviewed. Data were extracted from published studies and used for a narrative synthesis of evidence. A decision analytical economic model was identified and modified to assess the cost-effectiveness of PEG. One RCT and 17 non-randomised studies were reviewed for effectiveness. PEG substantially reduced and rapidly normalised IGF-1 levels in the majority of patients, approximately doubled GH levels, and improved some of the signs and symptoms of the disease. Tumour size was unaffected at least in the short term. PEG had a generally safe adverse event profile but a few patients were withdrawn from treatment because of raised liver enzymes. An economic model was identified and adapted to estimate the lower limit for the cost-effectiveness of PEG treatment versus standard care. Over a 20 year time horizon the incremental cost-effectiveness ratio was £81,000/QALY and £212,000/LYG. To reduce this to £30K/QALY would require a reduction in drug cost by about one third. PEG is highly effective for improving patients' IGF-1 level. Signs and symptoms of disease improve but evidence is lacking about long term effects on improved signs and symptoms of disease, quality of life, patient compliance and safety. Economic evaluation indicated that if current standards (UK) for determining cost-effectiveness of therapies were to be applied to PEG it would be considered not to represent good value for money." @default.
• W2038068436 created "2016-06-24" @default.
• W2038068436 creator A5015107938 @default.
• W2038068436 creator A5026641967 @default.
• W2038068436 creator A5047963230 @default.
• W2038068436 creator A5090784666 @default.
• W2038068436 date "2009-10-08" @default.
• W2038068436 modified "2023-10-03" @default.
• W2038068436 title "Clinical effectiveness and cost-effectiveness of pegvisomant for the treatment of acromegaly: a systematic review and economic evaluation" @default.
• W2038068436 cites W123434114 @default.
• W2038068436 cites W1969665744 @default.
• W2038068436 cites W1977937731 @default.
• W2038068436 cites W1999552666 @default.
• W2038068436 cites W2002070825 @default.
• W2038068436 cites W2022401782 @default.
• W2038068436 cites W2022695623 @default.
• W2038068436 cites W2027842268 @default.
• W2038068436 cites W2036870697 @default.
• W2038068436 cites W2044036203 @default.
• W2038068436 cites W2045942594 @default.
• W2038068436 cites W2048330864 @default.
• W2038068436 cites W2068704610 @default.
• W2038068436 cites W2101632387 @default.
• W2038068436 cites W2106242215 @default.
• W2038068436 cites W2107724413 @default.
• W2038068436 cites W2110776312 @default.
• W2038068436 cites W2113016432 @default.
• W2038068436 cites W2114461739 @default.
• W2038068436 cites W2118341413 @default.
• W2038068436 cites W2126132809 @default.
• W2038068436 cites W2126750918 @default.
• W2038068436 cites W2129145699 @default.
• W2038068436 cites W2130644916 @default.
• W2038068436 cites W2139121959 @default.
• W2038068436 cites W2143791513 @default.
• W2038068436 cites W2147795491 @default.
• W2038068436 cites W2153200944 @default.
• W2038068436 cites W2155874267 @default.
• W2038068436 cites W2157482119 @default.
• W2038068436 cites W2161555684 @default.
• W2038068436 cites W2164303686 @default.
• W2038068436 cites W2169376102 @default.
• W2038068436 cites W4211196325 @default.
• W2038068436 cites W4376595377 @default.
• W2038068436 doi "https://doi.org/10.1186/1472-6823-9-20" @default.
• W2038068436 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2768727" @default.
• W2038068436 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19814797" @default.
• W2038068436 hasPublicationYear "2009" @default.
• W2038068436 type Work @default.
• W2038068436 sameAs 2038068436 @default.
• W2038068436 citedByCount "45" @default.
• W2038068436 countsByYear W20380684362012 @default.
• W2038068436 countsByYear W20380684362013 @default.
• W2038068436 countsByYear W20380684362014 @default.
• W2038068436 countsByYear W20380684362015 @default.
• W2038068436 countsByYear W20380684362016 @default.
• W2038068436 countsByYear W20380684362017 @default.
• W2038068436 countsByYear W20380684362018 @default.
• W2038068436 countsByYear W20380684362019 @default.
• W2038068436 countsByYear W20380684362020 @default.
• W2038068436 countsByYear W20380684362021 @default.
• W2038068436 countsByYear W20380684362022 @default.
• W2038068436 countsByYear W20380684362023 @default.
• W2038068436 crossrefType "journal-article" @default.
• W2038068436 hasAuthorship W2038068436A5015107938 @default.
• W2038068436 hasAuthorship W2038068436A5026641967 @default.
• W2038068436 hasAuthorship W2038068436A5047963230 @default.
• W2038068436 hasAuthorship W2038068436A5090784666 @default.
• W2038068436 hasBestOaLocation W20380684361 @default.
• W2038068436 hasConcept C112930515 @default.
• W2038068436 hasConcept C126322002 @default.
• W2038068436 hasConcept C141071460 @default.
• W2038068436 hasConcept C168563851 @default.
• W2038068436 hasConcept C177713679 @default.
• W2038068436 hasConcept C187212893 @default.
• W2038068436 hasConcept C197934379 @default.
• W2038068436 hasConcept C2777433750 @default.
• W2038068436 hasConcept C2778886798 @default.
• W2038068436 hasConcept C2984496839 @default.
• W2038068436 hasConcept C3019080777 @default.
• W2038068436 hasConcept C500440147 @default.
• W2038068436 hasConcept C60644358 @default.
• W2038068436 hasConcept C71315377 @default.
• W2038068436 hasConcept C71924100 @default.
• W2038068436 hasConcept C75480439 @default.
• W2038068436 hasConcept C86803240 @default.
• W2038068436 hasConceptScore W2038068436C112930515 @default.
• W2038068436 hasConceptScore W2038068436C126322002 @default.
• W2038068436 hasConceptScore W2038068436C141071460 @default.
• W2038068436 hasConceptScore W2038068436C168563851 @default.
• W2038068436 hasConceptScore W2038068436C177713679 @default.
• W2038068436 hasConceptScore W2038068436C187212893 @default.
• W2038068436 hasConceptScore W2038068436C197934379 @default.
• W2038068436 hasConceptScore W2038068436C2777433750 @default.
• W2038068436 hasConceptScore W2038068436C2778886798 @default.
• W2038068436 hasConceptScore W2038068436C2984496839 @default.
• W2038068436 hasConceptScore W2038068436C3019080777 @default.
• W2038068436 hasConceptScore W2038068436C500440147 @default.
• W2038068436 hasConceptScore W2038068436C60644358 @default.
• W2038068436 hasConceptScore W2038068436C71315377 @default.

• next